The use of hydroxychloroquine for COVID-19 has been extremely controversial. While numerous studies show that it is effective, the FDA advises not to take it.
The study, “Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?” revealed that a “larger effectiveness of hydroxychloroquine in patients with less severe COVID-19 disease.”
Included in the study were 539 patients diagnosed with COVID-19 who were hospitalized in Milan between Feb 24-May 17. The individuals were divided into three groups.. One group of patients received hydroxychloroquine one day after they were admitted to the hospital. Another received hydroxychloroquine and azithromycin. The third group received neither drug. According to the study, the percent of deaths in the groups were 27%, 23%, and 51%, respectively.
While some studies have found it effective many believe that it can lead to cardiovascular issues. The study stated, “These results from two different real-life settings (Italy and USA), conflict with those of two large randomized trials (Horby et al., 2020, World Health Organization, 2020). ”
The video below explains a study from Belgium and the use of low-dose Hydroxychloroquine for COVID-19.
